Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 5,472,988
  • Shares Outstanding, K 45,060
  • Annual Sales, $ 1,599 M
  • Annual Income, $ 713,700 K
  • 36-Month Beta 1.42
  • Price/Sales 3.45
  • Price/Cash Flow 6.73
  • Price/Book 2.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.01 +8.48%
on 04/26/17
126.15 -3.68%
on 04/28/17
-1.21 (-0.98%)
since 04/24/17
3-Month
112.01 +8.48%
on 04/26/17
153.58 -20.88%
on 02/28/17
-25.21 (-17.18%)
since 02/24/17
52-Week
97.52 +24.59%
on 06/27/16
169.89 -28.48%
on 02/21/17
+4.88 (+4.19%)
since 05/24/16

Most Recent Stories

More News
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017

ALIOF : 284.0500 (+0.63%)
GILD : 64.36 (-0.51%)
MDT : 85.03 (+0.50%)
UTHR : 121.40 (-0.05%)
Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 2.28% Sell Off

United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.01 to a high of $121.32. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low...

UTHR : 121.40 (-0.05%)
3D Systems and United Therapeutics Announce Bioprinting Agreement

3D Systems (NYSE: DDD) and United Therapeutics Corporation (NASDAQ: UTHR) today announced plans to develop solid-organ scaffolds for human transplants. The multi-year collaboration and development agreement...

DDD : 22.53 (+0.72%)
UTHR : 121.40 (-0.05%)
United Therapeutics Corporation Reports First Quarter 2017 Financial Results

United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2017.

UTHR : 121.40 (-0.05%)
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More

Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let's see how things are shaping up for this quarter.

JNJ : 127.46 (-0.05%)
MDCO : 40.01 (-2.30%)
AMGN : 154.88 (+0.53%)
GSK : 42.94 (-0.05%)
UTHR : 121.40 (-0.05%)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market to Grow at a CAGR of 3.2%, 2017-2021 with Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis & United Therapeutics Dominating - Research and Markets

Research and Markets has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021" report to their offering.

NVS : 81.38 (+0.39%)
UTHR : 121.40 (-0.05%)
United Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market Opens On Wednesday, April 26, 2017

United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its first quarter 2017 financial results before the market opens on Wednesday, April 26, 2017.

UTHR : 121.40 (-0.05%)
PolarityTE(TM), Inc. Recruits Key Additions to Management

Michael V. Callahan, MD, DTM&H, MSPH named Director of Military and Mass Casualty Regenerative Medicine Programs; Cameron Hoyler, JD from King and Spalding's Life Sciences and Product Liability Practices...

COOL : 17.25 (+13.19%)
UTHR : 121.40 (-0.05%)
PolarityTE(TM), Inc. Recruits Key Additions to Management

Michael V. Callahan, MD, DTM&H, MSPH named Director of Military and Mass Casualty Regenerative Medicine Programs; Cameron Hoyler, JD from King and Spalding's Life Sciences and Product Liability Practices...

COOL : 17.25 (+13.19%)
UTHR : 121.40 (-0.05%)
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates

2017 is expected to be a strong year for drug stocks.

JNJ : 127.46 (-0.05%)
LLY : 77.92 (-0.09%)
AMGN : 154.88 (+0.53%)
UTHR : 121.40 (-0.05%)
BMY : 53.79 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.

See More

Support & Resistance

2nd Resistance Point 123.55
1st Resistance Point 122.51
Last Price 121.40
1st Support Level 120.46
2nd Support Level 119.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.